XNCR Xencor InccompanySEC Filings & Insider Trading Activity 2026
Latest Xencor Inc (XNCR) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 25, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on April 27, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Xencor Inc (XNCR) (SEC CIK 1326732), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Clinical-stage biopharma developing engineered XmAb antibody therapeutics targeting cancer and autoimmune diseases with modular bispecific Fc domain technology
- • New product emphasis: XmAb412, a bispecific antibody targeting TL1A and IL23p19 in autoimmune diseases, first-in-human studies planned for 2026
Risk Factors
- • Regulatory risk from FDA approvals with no products yet approved using XmAb platform, uncertain commercial viability of candidates
- • Geopolitical/macro risk from California concentration; wildfires or earthquakes could disrupt operations and third-party supply continuity
Management Discussion & Analysis
- • Revenue $125.6M in 2025, up $15.1M YoY from $110.5M in 2024, driven by Alexion and Incyte license agreements
- • Operating loss $177.5M in 2025, nearly flat vs $178.4M in 2024, representing an operating margin of -141.3% vs -161.4%
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New risk due to ongoing U.S. government shutdown since October 1, 2025, causing FDA and SEC furloughs, delaying regulatory reviews and capital access
- • Material update on regulatory risk: IRA drug price negotiations now effective, with 10 drugs priced from January 1, 2026, and 15 more selected for 2025 negotiations
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 1.02: Termination of a Material Definitive Agreement
- • Genentech terminating collaboration agreement with Xencor effective September 4, 2026 — "for convenience" clause invoked
- • Sole active drug (efbalropendekin alfa, engineered cytokine-Fc fusion) already cut from Roche's pipeline in January 2025 — termination largely expected
Item 7.01: Regulation FD Disclosure
- • Alexion (AstraZeneca sub) unilaterally stopped U.S. royalty payments on Ultomiris®, disputing obligation under existing license agreement
- • At risk: $100–$120M in aggregate royalties Xencor expected to receive through 2028 on U.S. Ultomiris sales
Annual Reports Archive10-K
AI-powered analysis of Xencor Inc (XNCR) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Xencor Inc (XNCR) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Xencor Inc (XNCR) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $164.6M | $168.3M | $110.5M | $125.6M |
| Operating Income | -$82.5M | -$138.6M | -$178.4M | -$177.5M |
| Net Income | -$55.2M | -$126.1M | -$232.6M | -$91.9M |
| Op. Margin | -50.1% | -82.4% | -161.5% | -141.4% |
| Net Margin | -33.5% | -74.9% | -210.5% | -73.2% |
| Balance Sheet | ||||
| Total Assets | $846.3M | $952.7M | $951.9M | $875.5M |
| Equity | $727.5M | $668.8M | $677.6M | $635.6M |
| ROE | -7.6% | -18.9% | -34.3% | -14.5% |
Source: XBRL financial data from Xencor Inc (XNCR) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 27, 2026 | — | — | — |
8-K | Mar 9, 2026 | — | Analysis | — |
8-K | Mar 4, 2026 | — | Analysis | — |
10-K | Feb 25, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 25, 2026 | — | Analysis | — |
8-K | Jan 8, 2026 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | — | |
10-Q | May 7, 2025 | Mar 31, 2025 | — | |
10-K | Feb 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 5, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Feb 29, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 8, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 8, 2023 | Mar 31, 2023 | — | |
10-K | Feb 27, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 7, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 3, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Feb 24, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 8, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 4, 2021 | Jun 30, 2021 | — | |
10-Q | May 5, 2021 | Mar 31, 2021 | — |
Frequently Asked Questions
What are the latest XNCR SEC filings in 2026?
Xencor Inc (XNCR) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on April 27, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did XNCR file its most recent 10-K annual report?
Xencor Inc (XNCR) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view XNCR 10-Q quarterly reports?
Xencor Inc (XNCR)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every XNCR 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has XNCR filed recently?
Xencor Inc (XNCR)'s most recent 8-K was filed on April 27, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find XNCR insider trading activity (Form 4)?
SignalX aggregates every XNCR Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does XNCR file with the SEC?
Xencor Inc (XNCR) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new XNCR filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Xencor Inc (XNCR).
What is XNCR's SEC CIK number?
Xencor Inc (XNCR)'s SEC CIK (Central Index Key) number is 1326732. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1326732 to look up all XNCR filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find XNCR return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Xencor Inc (XNCR) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Xencor Inc SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 53+ filings.